Since angiotensin-converting enzyme inhibitors (ACEIs) were first introduced in the 1980s for treatment of hypertension and congestive heart failure, there has been progressive increase in use due to these and other new indications. This fact has led to a parallel increase in adverse effects induced by ACEIs, mainly angioedema, with different degrees of severity.
INTRODUCTION
Drug-induced angioedema may be caused by a wide range of drugs, the most important being the NSAIDs, antibiotics and angiotensin-converting enzyme inhibitors (ACEIs) [1] . ACEIs were first introduced in 1981 for treatment of hypertension and congestive heart failure. During the past decade, they have also been used for preserving renal function in diabetic patients and as treatment of hypertensive/renal crisis in scleroderma patients [2, 3] . These new indications have increased its consumption, being among the most commonly prescribed drugs in USA (4.2% of the total prescriptions) [4] .
ACEIs can be divided into three groups based on their molecular structure: sulfhydryl-containing agents (Captopril, Zofenopril), dicarboxylatecontaining agents (Enalapril, Ramipril, Quinapril, Perindopril, Lisinopril, Benazepril, Imidapril, ofenopril, Trandolapril) and phosphonate-containing agents (Fosinopril). ACEIs block the ACE activity that catalyzes the transformation of angiotensin I to angiotensin II, leading to an increase in bradykinin that lowers blood pressure, along with antiatherosclerotic, antithrombotic, anti-inflammatory and anti-ischemic effects [5, 6] . Side effects secondary to treatment with ACEIs are cough, skin rash, azotemia and angioedema [7] [8] [9] . ACEI-induced angioedema may be resistant to treatment and vary
PATHOLOGICAL MECHANISM OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA
The exact pathway by which ACEIs cause angioedema is not completely understood [11 & ,12] . ACEI-induced angioedema generally involves nonpruritic swelling of the skin and mucous membranes at different locations preferentially affecting lips, tongue, mouth, larynx, pharynx, or periorbital region [13] . Those cases with severe airway inflammation are potentially life-threatening [14] .
Angioedema is caused by an increase in permeability of submucosal or subcutaneous capillaries, with plasma extravasation frequently produced by high levels of histamine or bradykinin that could potentially differentiate an allergic from a nonallergic cause [13, 15] (see Fig. 1 ). The high concentrations of bradykinin will interact with vascular B-2 receptors causing vasodilatation, tissue and vascular permeability, and plasma extravasation into the interstitial space of subcutaneous or submucosal tissue [16] , and increased cyclic guanosine monophosphate (c-GMP) and release of nitric oxide [17] . In the airways, bradykinin produces cough and bronchoespasm via bradykinin receptor 2 [18] [19] [20] [21] [22] .
Angioedema induced by bradykinin can be divided into two groups: with deficiency in the C1-esterase inhibitor [hereditary angioedema (HAE) or acquired C-1 Inhibitor (INH) deficiency]; without C1-esterase inhibitor deficiency (estrogenrelated hereditary angioedema or induced by ACEIs) [11 & ,23]. Angiotensin-converting enzyme inhibitors cause bradykinin accumulation [24] [25] [26] and a slow processing of C-terminal arginine residues of bradykinin, contributing to retard the bradykinin metabolism and prolongation of its biological activity [20, 27, 28] . Several studies have associated ACEI-induced angioedema with alterations in the bradykinin metabolism, that is, the cleavage of bradykinin by angiotensin yields to aminopeptidase P (APP) inactivation of active metabolite des-Arg9bradykinin. Blais et al. [29] reported a defect in a serum enzyme involved in the des-Arg bradykinin metabolism in 50% of ACEI-induced angioedema patients. Other authors also reported a decrease of the activity of APP and dipeptidyl peptidase IV (DPPIV or CD26) in the substance P degradation pathways [27] . However, the precursor of bradykinin, kininogen, found in plasma in HAE, is not detected in ACEI-induced angioedema patients [30] , suggesting that the mechanism involved in this angioedema is more related with the bradykinin catabolism. Other enzymes also contribute to the degradation of bradykinin, such as neutralendopeptidase (enkephalinase or neprilysin) and aminopeptidase N [31] , which are not affected by ACEI intake. This could be the reason why not all the patients treated with ACEI will have problems because of the bradykinin increase.
EPIDEMIOLOGY AND RISK FACTORS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA
The most important drugs eliciting angioedema excluding NSAIDs and betalactams are ACEIs. Over the past years, ACEI consumption has increased to more than 40 million people worldwide [32] , so the prevalence of ACEI-induced angioedema is likely to increase [33] . ACEI represents one of the most frequent causes of recurrent drug-induced angioedema [34] , and a major cause for hospitalizations due to angioedema [35 && ]. The incidence is estimated to be 0.1-0.7% among ACEI-treated patients [36] . Recent publications indicate that this figure is higher, ranging from 2.2 to 6% [25] in clinical trials [37] or up to 8% in a nation-wide prevalence survey in Japan [38] . In a recent of retrospective study of a large population, Toh et al. [39 && ] reported an incidence of 4.38 cases of angioedema/1000 ACEI users compared with 1.66 cases in angiotensin receptor inhibitors [angiotensin II receptor blockers (ARBs)] or 1.67 cases in beta-blocker users.
KEY POINTS
ACEIs are a major cause of drug-induced angioedema caused by increase of bradykinin levels.
Female, African-American, elderly and genetically predisposed individuals are prone to develop ACEIinduced angioedema.
Several risk factors have been described for ACEIinduced angioedema such as female sex, age, ethnic origin, previous drug adverse reactions, other allergic diseases, smoking habit, obesity, upper airway surgery, trauma and immunosuppression in cardiac and renal transplant recipients [40, 41] . It is thought there is no dose-response relationship.
A female predominance has been reported [11 & ,34], with a high proportion of women experiencing an increase in the number of attacks during menstrual periods, pregnancy [42] , oral contraceptives and hormone replacement therapy [42] . All this could be related to the effect of female hormones in the increase of kininogen and kallikrein levels and bradykinin synthesis [43] . Incidence of ACEI-induced angioedema is 1.5 times higher in patients above 65 years [40] . Prevalence of ACEI-induced angioedema is five times higher in the African-American population than in Caucasians [44] . Data from clinical trials reported an incidence from 0.1 to 1.8% in black populations [45] . This could be related to reduced plasma activity and levels of APP that is involved in the inactivation of bradykinin and des-Arg-bradykinin, observed more frequently in women and African-American individuals [25, 31, 46, 47] . Moreover, the incidence of ACEI-induced angioedema is about four-fold higher among patients with a history of drug hypersensitivity [40] . Also, seasonal allergies have been identified as a risk factor for ACEI-induced angioedema, with an odds ratio (OR) 1.79 (1.06-3) [40] . On the contrary, diabetes has been associated with a lower risk of angioedema [11 & ]. Some studies [48, 49] indicate a higher risk of having or worsening angioedema after NSAID intake in patients treated with ACEIs. A study [48] including 60 patients showed that ACEIs and NSAIDs were the most common causative factors of angioedema; moreover, 6 out of 30 patients with concurrent treatment with an ACEI and an NSAID needed intubation. Thus, the concomitant use of ACEIs and NSAIDs should be avoided in patients with a history of angioedema, as the combination leads to more severe attacks. Angiotensin-converting enzyme inhibitor-induced angioedema Campo et al.
The time interval between the start of treatment and onset of clinical symptoms is extremely wide and variable, making it very difficult to estimate the prevalence [50] . One out of 2500 cases of ACEIinduced angioedema is presented within the first week and two-thirds during the 90 days of commencing the ACEI treatment. However, although less frequent, the symptom onset might be delayed by up to 7-10 years of ACEI use [25, 30, 51] . The subsequent incidence of angioedema is around 1 in 500 patients per year.
Angiotensin-converting enzyme inhibitorinduced angioedema has different degrees of severity, and up to 20% may be life-threatening, affecting the larynx and upper respiratory tract [33, 51] . From the large number of patients being treated with ACEIs worldwide, it is estimated that 1000 cases of severe angioedema can occur per year mainly due to laryngeal edema [11 & ]. Visceral angioedema also occur, although less frequently. The exact incidence is unknown since clinicians less readily recognize abdominal pain caused by ACEI-induced intestinal angioedema. The most commonly reported symptoms are abdominal pain, vomiting and watery diarrhea [52, 53] , and the most common radiological findings include ascites, small bowel wall thickening, dilatation without obstruction and straightening [54] .
Factors reducing bradykinin catabolism can induce high levels of plasma bradykinin and increase the frequency of the attacks and severity of ACEIinduced angioedema [55] [56] [57] . This has been observed in heart failure patients, where the disease per se alters bradykinin catabolism and may be implicated in the high rate of angioedema related to treatment with ACEIs and ARBs [57] . This has led to genetic studies on polymorphisms of enzymes involved in the metabolism of bradykinin, since predisposed individuals taking ACEIs may develop angioedema as a result of a reduced bradykinin clearance [15] .
There are several studies [46, 58] indicating that different polymorphisms of X-prolyl aminopeptidase 2 (XPNPEP2), a candidate gene encoding membrane-bound APP, are associated with ACEIinduced angioedema, being more common in women. These polymorphisms are different from the one associated with ACEI-induced cough, which is related to an insertion/deletion polymorphism of the human ACE gene on chromosome 17q23 [59] . A recent meta-analysis has associated the XPNPEP2 gene region with ACEI-induced angioedema in three studies [60 && ]. Three XPNPEP2 polymorphisms (c.-2399C>A, c.-1612G>T, and c.-393G>A) have been significantly associated with reduced plasma APP activity in a healthy population. Moreover, haplotype ATG, which functionally contributes to a reduction in APP, was significantly associated with the disease in a small group of patients with ACEI-induced angioedema [OR 4.87 (1.78-13.35); P ¼ 0.002] [61] .
CLINICAL FEATURES AND DIFFERENTIAL DIAGNOSIS
The clinical symptoms of ACEI-induced angioedema are similar to those observed in patients with C-1 INH deficiency mainly affecting the face, oral mucosa, tongue, lips, pharynx and larynx, predominantly asymmetric, and being potentially life-threatening when laryngeal edema develops [62, 63] . Abdominal and/or genital angioedema has been also reported, but the occurrence is less frequent [53, 64] . Life-threatening edema of the upper airway is present in approximately 40% of cases and can be resistant to treatment or even fatal [65] .
One of the main difficulties for diagnosing ACEI-induced angioedema is the time interval between the start of the treatment and the appearance of the reaction, which may range from hours to years, making it difficult to establish the temporal relationship with the causative drug [51] . Symptoms of angioedema secondary to ACEIs usually tend to resolve within 24-48 h of discontinuing the culprit drug. Some cases of late onset of angioedema may appear even weeks after the discontinuation of the ACEI [40, 66] .
Angiotensin-converting enzyme inhibitorinduced angioedema does not produce any specific biological marker, so it is very important to exclude other causes of angioedema, that is, those induced by drugs or allergens that are IgE-mediated, and also NSAID hypersensitivity [67] . It is generally accepted that ACEI-induced angioedema differs from drug allergic reactions and NSAID hypersensitivity in the clinical manifestations they induced. In this sense, it is very helpful to determine whether angioedema is associated with urticaria, since urticaria rarely appears in ACEI-induced angioedema. Lack of response to treatment with antihistamines, corticosteroids or adrenaline suggests ACEI-induced angioedema [66] . Furthermore, normal levels of complement factor 4 would favor a diagnosis of ACEI-induced angioedema rather than angioedema induced by C-1 INH deficiency.
TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-INDUCED ANGIOEDEMA
The management of ACEI-induced angioedema is similar to that of allergic angioedema, including withdrawal of the causing ACEI [12, 68, 69] . This has been widely shown in a follow-up study [70] of patients that had no further events in 85% of cases after drug intake was stopped. This study [68] also showed that in 15% of patients, there was another cause of angioedema other than ACEIs, for example, ARBs. Moreover, the importance of ACEI discontinuation has been highlighted in a study [71] that demonstrated the higher risk of recurrence of angioedema for patients who continued with the ACEI treatment compared with those who were treated with an alternative drug (19 vs. 2 per 100 patients/year).
Milder cases are usually managed with antihistamines (H 1 and H 2 blockers) and steroids, with resolution of symptoms within 24-48 h [55, 72] . In moderate and severe cases, intubation is elective for airway protection [15, 73] . Treatment with epinephrine may decrease the rate of swelling, but antihistamines and steroids have demonstrated little effect. In cases with severe angioedema, patients should be monitored for airway compromise and fatal complications because of the risk of relapses, despite withdrawal of the offending drug [72] .
Since ACEI-induced angioedema has a common pathway with HAE with increased levels of bradykinin, the treatments useful for HAE have been adapted for ACEI-induced angioedema [10,11 & ,13,74,75] . Severe angioedema after enalapril intake was effectively treated with C1-INH concentrate [76] . Other drugs such as recombinant C1-INH, which is a kallikrein inhibitor (ecallantide), and a specific bradykinin-B2-receptor antagonist (icatibant) [74, 75, [77] [78] [79] have been proposed. In a series of eight cases and in a case report, the use of icatibant shortened the resolution of angioedema compared with classic drugs [80, 81] . Fresh frozen plasma (FFP) [55, 76, 82] has also been shown to be useful for the treatment of ACEI-induced angioedema [62,83,84 & ]. The mechanism involved in the therapeutic effect of FFP is from angiotensin II present in plasma, which catalyzes the degradation of bradykinin excess. However, FPP can also contain complement components that can make the angioedema more severe and long-lasting. Thus, it is not recommended during an acute attack [85] . In spite of the promising results of these treatments [73, 81] , more studies need to be done in order to establish their efficacy and safety.
When ACEI-induced angioedema has been diagnosed, treatment with ACEI should be strictly avoided, and an alternative drug prescribed. A follow-up study [86] in a large group of ACEIinduced angioedema patients for 14 years showed that the interruption of ACEI and the switch to another antihypertensive drug prevented recurrences of angioedema in about 50% of patients. One of the candidate drugs are ARBs, which are involved in the inhibition of the renin-angiotensin system with no apparent direct effect on the inhibition of bradykinin breakdown. In general, ARBs are well tolerated by patients with ACEI-induced angioedema [87] , with angioedema occurring in a low percentage of patients [39 && ,68,88] . In a recent analysis of the literature, angioedema risk with ARBs was similar to placebo (relative risk 1.62; 95% confidence interval 0.17-15.79) [89 & ]. Moreover, an analysis of two randomized controlled trials [90, 91] , two retrospective cohorts and one meta-analysis estimated the incidence of angioedema in less than 10% of patients who receive an ARB after experiencing ACEI-associated angioedema. These angioedema cases were less severe and occurred earlier [92] . A pooled analysis of 31 studies in 12 188 patients showed the incidence of angioedema associated with the direct renin inhibitor, aliskiren monotherapy to be 0.4%, similar to that with ACE inhibitors with no serious angioedema events [93] . The mechanism seems to be related to bradykinin increase via the angiotensin II activation of angiotensin II type-2 (AT2) receptors and the subsequent inhibition of bradykinin breakdown [94, 95] . Therefore, ARBs may be an alternative but do not seem to completely solve the problem, and should be reserved for patients with high therapeutic need for angiotensin inhibition [92] .
CONCLUSION
Angiotensin-converting enzyme inhibitors are one of the most important drugs eliciting angioedema, which is caused by high levels of bradykinin secondary to ACE inhibition, producing vasodilatation, tissue/vascular permeability and increased c-GMP with release of nitric oxide (see Table 1 ). ACEI-induced angioedema has been associated with alterations in bradykinin metabolism and with polymorphisms of XPNPEP2 (À2399 A variant). The incidence ranges from 0.1 to 2.2%, and is increasing in recent years. Several risk factors may predispose to angioedema, such as female sex and being African-American. Most cases present within the first week to 90 days of treatment, although sometimes symptom onset may be delayed for years. The management of mild ACEI-induced angioedema includes the withdrawal of the causative drug, and administration of antihistamines and steroids. For moderate and severe cases, intubation and treatment with epinephrine may be required. Other treatments described include C-1 INH concentrates, FFP, kallikrein inhibitors such as ecallantide and bradykinin-B2-receptor antagonist such as icatibant. However, clinical trials are needed in order to establish their efficacy and safety. Once an ACEIinduced angioedema is diagnosed, the use of ARBs as alternative treatment has shown that less than 10% of patients with ACEI-associated angioedema developed new angioedema symptoms after ARB intake. Symptoms are often milder and occur earlier compared with angioedema developed during ACEI therapy. Therefore, ARBs may be an alternative drug for patients with high therapeutic need for angiotensin inhibition. 
